BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8258025)

  • 21. Unrelated donor bone marrow transplantation as treatment for chronic myeloid leukemia: the Spanish experience. The Chronic Myeloid Leukemia Subcommittee of the GETH. Grupo Español de Trasplante Hemopoyético.
    Carreras E; Tomás JF; Sanz G; Iriondo A; Boqué C; López J; Cabrera R; Sureda A; de Soria VG; Sierra J; Sanz MA; Torres A
    Haematologica; 2000 May; 85(5):530-8. PubMed ID: 10800172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).
    Ringdén O; Labopin M; Frassoni F; Sanz G; Demeocq F; Prentice H; Cahn JY; Barbui T; Meloni G; Schaefer U; Reiffers J; Gorin N
    Bone Marrow Transplant; 1999 Aug; 24(4):389-96. PubMed ID: 10467328
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of allogeneic hematopoietic stem cell transplantation with very-high-dose conditioning regimen for refractory leukemia].
    Liu QF; Sun J; Xu D; Zhang Y; Fan ZP; Wei YQ; Meng FY; Zhou SY
    Di Yi Jun Yi Da Xue Xue Bao; 2004 Oct; 24(10):1117-9. PubMed ID: 15485779
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination.
    Carlens S; Ringdén O; Aschan J; Hägglund H; Ljungman P; Mattsson J; Remberger M
    Clin Transplant; 1998 Apr; 12(2):84-92. PubMed ID: 9575394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic matched T-cell-depleted bone marrow transplantation for acute leukemia patients.
    Aristei C; Aversa F; Raymondi C; Marsella AR; Panizza BM; Perrucci E; Piro F; Maranzano E; Lupattelli M; Martelli MF; Latini P
    Cancer J Sci Am; 1996; 2(6):330-4. PubMed ID: 9166553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
    Long GD; Amylon MD; Stockerl-Goldstein KE; Negrin RS; Chao NJ; Hu WW; Nademanee AP; Snyder DS; Hoppe RT; Vora N; Wong R; Niland J; Reichardt VL; Forman SJ; Blume KG
    Biol Blood Marrow Transplant; 1997 Dec; 3(6):324-30. PubMed ID: 9502300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
    Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
    Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis. Acute Leukaemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation (EBMT) and the International Marrow Unrelated Search and Transplant (IMUST) Study.
    Ringdén O; Labopin M; Gluckman E; Hows JM; Bradley BA; Kolb HJ; Fouillard L; Jacobsen N; Vernant JP; Witz F; Harousseau JL; Gorin NC
    Bone Marrow Transplant; 1997 May; 19(10):963-8. PubMed ID: 9169639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.
    Majhail NS; Parks K; Defor TE; Weisdorf DJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
    Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
    Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: toxicity and outcome.
    Rubin CM; Mick R; Johnson FL
    Bone Marrow Transplant; 1996 Sep; 18(3):533-40. PubMed ID: 8879614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unrelated bone marrow transplantation for high-risk anaplastic large cell lymphoma in pediatric patients: a single center case series.
    Cesaro S; Pillon M; Visintin G; Putti MC; Gazzola MV; D'Amore E; Scarzello G; Zanesco L; Messina C; Rosolen A
    Eur J Haematol; 2005 Jul; 75(1):22-6. PubMed ID: 15946306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell-depleted autologous marrow fails to prevent acute graft-versus-host disease after allogeneic marrow transplantation for lymphoblastic lymphoma.
    Przepiorka D; Giralt S; Huh YO; Andreeff M; Luna M; Reading C; Thomas M; Champlin RE
    Transplant Proc; 1992 Dec; 24(6):2906-7. PubMed ID: 1465994
    [No Abstract]   [Full Text] [Related]  

  • 37. Allogeneic bone marrow transplantation for acute lymphoblastic leukaemia.
    Barrett AJ
    Leukemia; 1992; 6 Suppl 2():139-43. PubMed ID: 1578917
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk factors for early mortality in allogeneic bone marrow transplantation. A multivariate analysis on 174 leukaemia patients.
    Valls A; Algara M; Marrugat J; Carreras E; Sierra J; Grañena A
    Eur J Cancer; 1993; 29A(11):1523-8. PubMed ID: 8217355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Low early mortality after allogeneic bone marrow transplantation thanks to rigorous sterility measures, modified whole body irradiation, cyclosporin A and antiviral precautions].
    Gmür J; Burger J; Frick P
    Schweiz Med Wochenschr; 1985 Oct; 115(43):1524-5. PubMed ID: 3001930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Allogeneic bone marrow transplantation for acute lymphoblastic leukemia].
    Yamauchi T; Ohno R
    Nihon Rinsho; 1990 Sep; 48(9):2073-9. PubMed ID: 2232212
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.